To evaluate the efficacy and safety of B013 in patients with platinum-resistant recurrent ovarian cancer.
Subjects who voluntarily participate in this study and sign informed consent form;
Ovarian cancer, fallopian tube cancer or primary peritoneal cancer confirmed by histopathological examination and meeting the criteria for platinum resistance recurrence;
ECOG performance status of 0 or 1；
Expected survival > 12 weeks;
Subjects who have received prescribed treatment previously;
Subjects who are still using anti-tumor traditional Chinese patent medicines at the time of signing informed consent;
Subjects with known central nervous system metastasis and multiple bone metastasis;
Subjects who had clinical symptoms of pleural effusion, pericardial effusion or ascites before randomization and needed puncture drainage, or had received puncture drainage within the previous 2 weeks;
Shanghai Jiaolian Drug Research and Development Co., Ltd
Lead sponsor
Shanghai Pharmaceuticals Holding Co., Ltd
Collaborator